Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CeNeRx BioPharma has started a double blind, placebo-controlled Phase II trial of TriRima as a treatment for resistant depression.
Subscribe to our email newsletter
The trial is designed to assess the efficacy of TriRima administered twice daily as monotherapy in patients with treatment resistant depression.
CeNeRx chief medical officer Daniel Burch said that they are eager to test the efficacy of their new formulation of TriRima in treatment resistant depression, and they are delighted that the Phase II trial is now enrolling patients.
"The new formulation of TriRima has demonstrated excellent safety in multiple studies to date, and we believe that it has the potential to become the first agent to achieve the triple action efficacy of MAO inhibitor drugs without their limiting side effects," Burch said.